Analysts Set Expectations for K2M Group Holdings, Inc.’s Q3 2017 Earnings (KTWO)
K2M Group Holdings, Inc. (NASDAQ:KTWO) – William Blair issued their Q3 2017 EPS estimates for K2M Group Holdings in a research report issued on Monday. William Blair analyst K. Krum anticipates that the medical device company will earn ($0.18) per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for K2M Group Holdings’ Q4 2017 earnings at ($0.15) EPS, FY2017 earnings at ($0.80) EPS, Q1 2018 earnings at ($0.20) EPS, Q2 2018 earnings at ($0.14) EPS, Q3 2018 earnings at ($0.10) EPS, Q4 2018 earnings at $0.01 EPS and FY2018 earnings at ($0.43) EPS.
K2M Group Holdings (NASDAQ:KTWO) last posted its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. K2M Group Holdings had a negative net margin of 16.21% and a negative return on equity of 15.45%. The firm had revenue of $65.70 million during the quarter, compared to analyst estimates of $66.26 million. During the same quarter in the prior year, the business posted ($0.27) earnings per share. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/11/analysts-set-expectations-for-k2m-group-holdings-inc-s-q3-2017-earnings-ktwo.html.
K2M Group Holdings (NASDAQ KTWO) opened at 18.01 on Wednesday. The company has a 50-day moving average of $21.94 and a 200 day moving average of $22.52. The firm’s market cap is $779.26 million. K2M Group Holdings has a 52-week low of $16.32 and a 52-week high of $25.99.
Institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA grew its holdings in shares of K2M Group Holdings by 5,175.3% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,484 shares of the medical device company’s stock valued at $109,000 after purchasing an additional 4,399 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of K2M Group Holdings by 9.1% during the 1st quarter. Legal & General Group Plc now owns 6,763 shares of the medical device company’s stock valued at $138,000 after purchasing an additional 564 shares during the last quarter. Dorsey & Whitney Trust CO LLC bought a new stake in shares of K2M Group Holdings during the 2nd quarter valued at approximately $211,000. American International Group Inc. grew its holdings in shares of K2M Group Holdings by 7.1% during the 1st quarter. American International Group Inc. now owns 15,847 shares of the medical device company’s stock valued at $325,000 after purchasing an additional 1,047 shares during the last quarter. Finally, Symphony Asset Management LLC bought a new stake in shares of K2M Group Holdings during the 2nd quarter valued at approximately $351,000. 97.86% of the stock is currently owned by institutional investors.
In related news, insider John Philip Md Kostuik sold 1,332 shares of K2M Group Holdings stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $23.30, for a total transaction of $31,035.60. Following the sale, the insider now directly owns 200,629 shares of the company’s stock, valued at approximately $4,674,655.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Gregory S. Cole sold 39,357 shares of K2M Group Holdings stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $23.37, for a total transaction of $919,773.09. The disclosure for this sale can be found here. Insiders sold a total of 44,129 shares of company stock valued at $1,033,644 over the last 90 days. Corporate insiders own 5.80% of the company’s stock.
About K2M Group Holdings
K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.
Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.